These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Protection of turkeys against haemorrhagic enteritis by monoclonal antibody and hexon immunization.
    Author: van den Hurk JV, van Drunen Littel-van den Hurk S.
    Journal: Vaccine; 1993; 11(3):329-35. PubMed ID: 8383383.
    Abstract:
    Virus-neutralizing monoclonal antibodies specific for the hexon of haemorrhagic enteritis virus (HEV), a turkey adenovirus, were examined for their ability to confer passive protection against haemorrhagic enteritis (HE) in turkeys. A high dose of antibody prevented clinical disease and reduced virus replication in experimentally infected birds. This suggests that virus neutralization might be an important mechanism for protection against HE. Subsequently, the use of the hexon protein as a subunit vaccine was investigated by immunizing birds with affinity-purified HEV hexon. The birds were tested for the appearance of hexon-specific antibodies in their sera, for protection from clinical disease, and prevention of virus replication after challenge with virulent HEV (HEV-V). Regardless of whether birds were immunized with native or denatured hexon, high ELISA antibody titres were produced to each immunogen. A virus-neutralizing antibody response was induced by immunization with the native hexon but not by immunization with the denatured protein. All turkeys twice immunized with a dose of at least 1 microgram, and four out of five birds immunized with two doses of 0.3 micrograms of purified native hexon, were protected against virus-induced disease and virus replication. In contrast, birds inoculated with denatured hexon were not protected. These results demonstrate the importance of the native (trimeric) structure of the hexon protein for eliciting a protective immune response. The impact of these results on the development of a vaccine for HE in turkeys produced by recombinant DNA technology is discussed.
    [Abstract] [Full Text] [Related] [New Search]